Figure 3 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome

Le résumé fourni par la source

Lynch syndrome–associated cancers frequently carry additional alterations in MMR- and genomic stability–associated genes. A, Oncoplot showing the mutational landscape across tumors, classified into three groups based on cancer chronology. Genes are ordered by decreasing mutation frequency. Annotations include TMB (Mut/Mb), the number of NOUS-209 FSMs, and tumor type. In the TMB and NOUS-209 annotation bars, lighter shades indicate samples not confirmed as MSI. B and C, Boxplots depict the distribution of TMB and NOUS-209 FSM in samples without mutations and in those with at least one mutation in POLD1, POLE, MSH3, and MSH6 genes. D and E, Mosaic plot showing the distribution of tumor stage for colorectal cancer and muscle invasion for urothelial cancer, stratified by the presence (at least one mutation) or absence of mutations of no mutation or at least one mutation in POLE, POLD1, MSH3, or MSH6 genes. CRC, colorectal cancer; UC, urothelial cancer.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.